Based on these findings, dual inhibition of DKC1 and MEK1/2 synergistically suppressed the growth of colorectal cancer cells both in vivo and in vitro, which may be of benefit for future clinical trials to treat CRC patients with DKC1 overexpression (Figure 7F). Here, MAP2K1 is linked to colorectal carcinoma.